留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

1例重症患者抗感染个体化给药策略分析

石晓萍,  吕迁洲,  杨婉花,  方洁

downloadPDF
文章导航 > 药学实践与服务  > 2017 >  35(6): 554-558
石晓萍, 吕迁洲, 杨婉花, 方洁. 1例重症患者抗感染个体化给药策略分析[J]. 药学实践与服务, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
引用本文: 石晓萍, 吕迁洲, 杨婉花, 方洁. 1例重症患者抗感染个体化给药策略分析[J]. 药学实践与服务, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
shu
SHI Xiaoping, LYU Qianzhou, YANG Wanhua, FANG Jie. The individualized anti-infective treatment strategy for a critically ill patient[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
Citation: SHI Xiaoping, LYU Qianzhou, YANG Wanhua, FANG Jie. The individualized anti-infective treatment strategy for a critically ill patient[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
shu

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018
  • 1.

    复旦大学附属中山医院药剂科, 上海 200032

  • 2.

    上海交通大学医学院附属瑞金医院药剂科, 上海 200025

The individualized anti-infective treatment strategy for a critically ill patient

  • 1.

    Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China

  • 2.

    Department of Pharmacy, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China

  • 摘要: 目的 探讨对于重症感染的患者如何根据其特殊的病理生理状况制订个体化抗感染治疗方案。 方法 临床药师参与1例急性泛发性发疹性脓疱病继发血流感染和肺部感染患者的抗感染治疗，通过分析其病理生理状况，运用治疗药物监测，协助临床医生制订个体化的给药方案。 结果 患者初始抗感染治疗方案效果不佳，临床药师根据患者的个体情况和血药浓度监测结果调整给药方案，患者的感染得到控制，病情好转。 结论 确保重症患者给药剂量达到药动学/药效学目标值是治疗成功的关键。
    Abstract: Objective To design individualized anti-infective therapy for a critically ill patient. Methods Based on pathophysiological conditions and therapeutic drug levels,clinical pharmacists assisted physicians to optimize individual anti-infective medication regimens for a patient with acute generalized exanthematous pustulosis secondary to blood stream infection and pulmonary infection. Results The patient responded poorly to initial treatment. After the medication regimen adjustments byclinical pharmacists according to the individual situation and therapeutic drug monitoring results,patient's condition was improved and the infection was under control. Conclusion The key to successful treatment is to ensure the dosage administered to the critically ill patients reach the target value of pharmacokinetics and pharmacodynamics.
  • [1] Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J]. Clin Infect Dis, 2011,52(3):e18-e55.
    [2] Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care:a standardised loading dose results in earlier therapeutic levels[J]. Intern Med J, 2012,42(1):23-29.
    [3] 万古霉素临床应用剂量专家组. 万古霉素临床应用剂量中国专家共识[J]. 中华传染病杂志, 2012,30(11):641-646.
    [4] 桑德福. 热病:桑德福抗微生物治疗指南[M]. 范洪伟译. 44版.北京:中国协和医科大学出版社, 2014:96-109.
    [5] Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists[J]. Clin Biochem Rev, 2010,31(1):21-24.
    [6] van Hal SJ, Fowler VJ. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?[J]. Clin Infect Dis, 2013,56(12):1779-1788.
    [7] Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill:challenges and potential solutions[J]. Lancet Infect Dis, 2014,14(6):498-509.
    [8] Rostas SE, Kubiak DW, Calderwood MS. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity[J]. Clin Ther, 2014,36(7):1098-1101.
    [9] Arimura Y, Yano T, Hirano M, et al. Mitochondrial superoxide production contributes to vancomycin-induced renal tubular cell apoptosis[J]. Free Radic Biol Med, 2012,52(9):1865-1873.
    [10] Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis[J]. Antimicrob Agents Chemother, 1996,40(10):2428-2430.
    [11] Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods[J]. J Antimicrob Chemother, 2003,51(4):857-864.
    [12] Singh SR, Bacon AR, Young DC, et al. In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2009,53(10):4495-4497.
    [13] Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2003,47(9):3002-3004.
    [14] Beibei L, Yun C, Mengli C, et al. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections:meta-analysis of randomised controlled trials[J]. Int J Antimicrob Agents, 2010,35(1):3-12.
    [15] 穆玉, 范春芳, 朱铁梁, 等. 重症患者利奈唑胺所致血小板减少危险因素分析[J]. 中国感染与化疗杂志, 2012,12(1):10-14.
    [16] Kalil AC, Metersky ML, Klompas M, et al. Executive summary:management of adults with hospital-acquired and ventilator-associated pneumonia:2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016,63(5):575-582.
    [17] Zelenitsky SA, Harding GK, Sun S, et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia:an antibiotic pharmacodynamic analysis[J]. J Antimicrob Chemother, 2003,52(4):668-674.
    [18] Kato H, Hagihara M, Hirai J, et al. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen[J]. Drugs RD, 2017,17(1):177-187.
    [19] Duszynska W, Taccone FS, Hurkacz M, et al. Therapeutic drug monitoring of amikacin in septic patients[J]. Crit Care, 2013,17(4):R165.
    [20] 付双双, 唐惠林, 段京莉. 抗感染药物治疗药物监测的Meta分析[J]. 中国新药杂志, 2013,22(15):1840-1848.
    [21] 梅清, 喻婷, 朱玉林, 等. 万古霉素单用及联合利福平或磷霉素对耐甲氧西林金黄色葡萄球菌防耐药突变浓度的研究[J]. 中国药理学通报, 2011,27(7):944-947.
    [22] 胡文, 邓国泉, 伍婷, 等. 万古霉素单用与联用磷霉素治疗耐甲氧西林金黄色葡萄球菌肺部感染的疗效比较[J]. 实用中西医结合临床, 2012,12(4):6-7.
    [23] 中华医学会呼吸病学分会《雾化吸入疗法在呼吸疾病中的应用专家共识》制定专家组. 雾化吸入疗法在呼吸疾病中的应用专家共识[J]. 中华医学杂志, 2016,96(34):2696-2708.
  • [1] 罗晶晶, 吴新安, 薛刚, 解正东, 叶剑波, 戎成婷.  临床药师参与1例足部损伤患者术后MRSA感染治疗的药学监护 . 药学实践与服务, 2022, 40(3): 286-288. doi: 10.12206/j.issn.1006-0111.202102004
    [2] 段晶晶, 纪国文, 郭芷君, 徐峰.  HPLC-MS/MS测定人血清中丙戊酸钠和万古霉素的浓度 . 药学实践与服务, 2022, 40(4): 350-353, 378. doi: 10.12206/j.issn.1006-0111.202108087
    [3] 屈茹楠, 毛峻琴, 信如娟, 张贺, 高岸.  1例化脓性血栓静脉炎继发肺部感染患者的药物治疗分析 . 药学实践与服务, 2022, 40(2): 171-174. doi: 10.12206/j.issn.1006-0111.202107045
    [4] 姜楠, 任海霞, 莫广艳.  1例尿毒症合并耐碳青霉烯肺炎克雷伯菌感染患者的药学监护 . 药学实践与服务, 2021, 39(4): 384-386. doi: 10.12206/j.issn.1006-0111.202007016
    [5] 章斌, 董云玲, 解莹馨, 李悦悦, 焦秀秀, 原永芳.  万古霉素致腹膜透析患者全血细胞减少的用药分析与不良反应监护 . 药学实践与服务, 2021, 39(2): 169-173. doi: 10.3969/j.issn.1006-0111.202008042
    [6] 李燕, 陈礼治, 王学彬, 杨云云, 杨小琳, 王卓.  Smart Dose对万古霉素血药浓度的预测效能评价 . 药学实践与服务, 2021, 39(2): 164-168, 177. doi: 10.12206/j.issn.1006-0111.202009010
    [7] 程彩奕, 邓冬梅, 王显凤, 杨征, 幸海燕.  二维液相色谱法测定脑脊液中替加环素浓度及其临床应用 . 药学实践与服务, 2020, 38(6): 543-546. doi: 10.12206/j.issn.1006-0111.202003040
    [8] 陆灏迪, 唐莲, 方洁, 薛盛敏, 尚尔宁, 薛苏冬.  肾功能亢进患者应用万古霉素致急性肾损伤的用药监护 . 药学实践与服务, 2019, 37(3): 274-278. doi: 10.3969/j.issn.1006-0111.2019.03.017
    [9] 应茵, 夏仲尼, 朱珺, 邹杰.  1例化脓性脑膜炎伴肾功能不全小儿患者的治疗分析与药学监护 . 药学实践与服务, 2018, 36(3): 285-288. doi: 10.3969/j.issn.1006-0111.2018.03.021
    [10] 郑丽丽, 轩辕欢, 姜倩, 范芳芳, 姚莉, 赵生俊.  比较万古霉素持续输注与间断输注引起肾毒性的荟萃分析 . 药学实践与服务, 2018, 36(2): 136-139,146. doi: 10.3969/j.issn.1006-0111.2018.02.009
    [11] 陈淑敏, 田文园, 边萌, 张杰.  老年重症感染患者万古霉素高谷浓度用药方案的探讨 . 药学实践与服务, 2014, 32(3): 216-219. doi: 10.3969/j.issn.1006-0111.2014.03.014
    [12] 张明媛, 常靓, 刘长海, 陈秋芬, 张军东, 陆峰.  柱前衍生化高效液相色谱法检测硫酸阿米卡星注射液中卡那霉素含量的改进 . 药学实践与服务, 2013, 31(5): 344-346. doi: 10.3969/j.issn.1006-0111.2013.05.006
    [13] 陈淑敏, 田文园, 张杰, 边萌.  我院32例万古霉素血药浓度监测结果与临床疗效分析 . 药学实践与服务, 2013, 31(3): 204-206,209. doi: 10.3969/j.issn.1006-0111.2013.03.012
    [14] 傅翔, 侯华健.  我院2005年万古霉素类药物利用评价 . 药学实践与服务, 2007, (3): 181-183.
    [15] 徐俊, 王钦敏.  HPLC法测定脑脊液中去甲万古霉素的浓度 . 药学实践与服务, 2000, (6): 379-380.
    [16] 尹玉琴, 蒋思强, 田梅兰, 邹静, 徐贵丽.  消可治与阿米卡星,妥布霉素的体外抗生素后效应研究 . 药学实践与服务, 2000, (6): 370-371,378.
    [17] 方士年, 王佑国, 崔光运.  硫酸阿米卡星注射液与其它药物在输液中的配伍变化 . 药学实践与服务, 1999, (6): 342-343.
    [18] 王建, 刘会臣, 侯艳宁.  高效毛细管电泳在临床药理中的应用 . 药学实践与服务, 1999, (2): 75-77.
    [19] 朱全刚, 哈明凤.  "红人综合征":万古霉素反应的病例报告 . 药学实践与服务, 1990, (4): 23-24.
    [20] 王晓波.  万古霉素两种给药方案的稳态药物动力学 . 药学实践与服务, 1988, (2): 72-72.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2608
  • HTML全文浏览量:  330
  • PDF下载量:  621
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-01-19
  • 修回日期:  2017-06-12

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018
  • 1. 复旦大学附属中山医院药剂科, 上海 200032
  • 2. 上海交通大学医学院附属瑞金医院药剂科, 上海 200025
  • 收稿日期: 2017-01-19
  • 修回日期: 2017-06-12

摘要: 目的 探讨对于重症感染的患者如何根据其特殊的病理生理状况制订个体化抗感染治疗方案。 方法 临床药师参与1例急性泛发性发疹性脓疱病继发血流感染和肺部感染患者的抗感染治疗，通过分析其病理生理状况，运用治疗药物监测，协助临床医生制订个体化的给药方案。 结果 患者初始抗感染治疗方案效果不佳，临床药师根据患者的个体情况和血药浓度监测结果调整给药方案，患者的感染得到控制，病情好转。 结论 确保重症患者给药剂量达到药动学/药效学目标值是治疗成功的关键。

English Abstract

石晓萍, 吕迁洲, 杨婉花, 方洁. 1例重症患者抗感染个体化给药策略分析[J]. 药学实践与服务, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
引用本文: 石晓萍, 吕迁洲, 杨婉花, 方洁. 1例重症患者抗感染个体化给药策略分析[J]. 药学实践与服务, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
shu
SHI Xiaoping, LYU Qianzhou, YANG Wanhua, FANG Jie. The individualized anti-infective treatment strategy for a critically ill patient[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
Citation: SHI Xiaoping, LYU Qianzhou, YANG Wanhua, FANG Jie. The individualized anti-infective treatment strategy for a critically ill patient[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
shu

    全文HTML

参考文献 (23)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计